GAITHERSBURG, Md., June 23, 2011 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com ) announced today that the company has signed a partnership agreement with Guangdong Zhongsheng Pharmaceutical Co. Ltd., a Chinese pharmaceutical company trading on the Shenzhen Stock Exchange (SZSE: 002317). The partnership will focus on development of small interfering RNA (siRNA) therapeutics to treat diabetic retinopathy and age-related macular degeneration. This is the second partnership deal for Sirnaomics with a publicly traded Chinese pharmaceutical company – following the one signed six months ago with Guangzhou Xiangxue Pharmaceutical Co. Ltd. (SZSE: 300147) ( PRNewswire news release on December 2nd, 2010 ).
Sirnaomics is a leading biopharmaceutical company in the discovery and development of RNA interference (RNAi) therapeutics. With its proprietary technologies using multi-targeted siRNA cocktail design and nanoparticle-enhanced therapeutic delivery, Sirnaomics has developed an enriched pipeline of siRNA therapeutic product candidates, including STP705 for scarless wound healing, STP601 for ocular diseases, STP702 for respiratory influenza viral infection, STP801 for lung cancer amongst other programs. While maintaining its IP portfolio with global rights, Sirnaomics has authorized its Chinese affiliate Suzhou Sirnaomics Pharmaceutical Co. Ltd. to hold and further develop the company's intellectual property rights in China.
The current partnership will pursue clinical development and commercialization of Sirnaomics' therapeutic product candidate (STP601), for treatment of ocular neovascularization conditions, in the Greater China and Southeast Asia markets. Sirnaomics previously completed a pre-IND meeting with the US FDA and determined on